CollPlant Biotechnologies Q4 Adj EPS $(0.35) Misses $(0.07) Estimate, Sales $299.00K Miss $8.56M Estimate
Portfolio Pulse from Benzinga Newsdesk
CollPlant Biotechnologies reported Q4 adjusted EPS of $(0.35), missing the $(0.07) estimate, and sales of $299K, missing the $8.56M estimate. This represents a 415.52% increase in sales compared to the same period last year.

April 04, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CollPlant Biotechnologies reported a significant miss in both adjusted EPS and sales for Q4, with adjusted EPS at $(0.35) versus the $(0.07) estimate and sales at $299K versus the $8.56M estimate.
The significant miss in both earnings and sales expectations for CollPlant Biotechnologies is likely to negatively impact investor sentiment in the short term. The magnitude of the miss, especially in sales which were 96.51% below the estimate, indicates potential underlying issues that could concern investors. Despite the year-over-year increase in sales, the failure to meet analyst expectations by such a wide margin could lead to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100